✦ LIBER ✦

Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy

✍ Scribed by David Palma; Tom Pickles

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 41 KB
Volume: 112
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23423

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Duration of testosterone suppression and

Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy

✍ Anthony V. D'Amico; Andrew A. Renshaw; Brittany Loffredo; Ming-Hui Chen 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

## Abstract ## BACKGROUND. The authors evaluated whether the duration of androgen suppression (AS) after the completion of hormone therapy (HT) was associated with the risk of prostate cancer‐specific mortality (PCSM) and all‐cause mortality (ACM). ## METHODS. The study cohort was comprised of 2

Reply to Duration of Testosterone Suppre

Reply to Duration of Testosterone Suppression and the Risk of Death from Prostate Cancer in Men Treated Using Radiation and 6 Months of Hormone Therapy

✍ Anthony V. D'Amico; Ming-Hui Chen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB 👁 2 views

Prostate cancer-specific mortality and t

Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer

✍ Karen E. Hoffman; Ming-Hui Chen; Brian J. Moran; Michelle H. Braccioforte; Danie 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

Short- vs long-term androgen suppression

Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate

✍ Anthony V. D'Amico; James W. Denham; Michel Bolla; Laurence Collette; David S. L 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

## Abstract ## BACKGROUND The study evaluated whether the use of 3 years as compared with 6 months of androgen suppression therapy (AST) combined with external beam radiation therapy (RT) in the treatment of high‐risk prostate cancer was associated with prolonged survival in advanced age men. ##

The risk of renal impairment in hormone-

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

✍ William K. Oh; Kevin Proctor; Mari Nakabayashi; Carolyn Evan; Lauren K. Tormey; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

Pretreatment prostate-specific antigen v

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

✍ David Palma; Scott Tyldesley; Tom Pickles; for the Prostate Cohort Outcomes Init 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

## Abstract ## BACKGROUND In men with prostate cancer, pretreatment prostate‐specific antigen (PSA) velocity (PSAV) has been demonstrated as a predictor of biochemical and survival outcomes in patients undergoing radical prostatectomy (RP). The utility of pretreatment PSAV in predicting outcomes a